Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Session Chair

Vishal A. Patel, MD

Director of Cutaneous Oncology
GW Cancer Center
Associate Professor of Dermatology and Oncology
George Washington University
School of Medicine & Health Sciences
Washington, DC

Disclosures

Vishal A. Patel, MD, has the following relevant financial relationships:
Consultant or advisor for: Almirall; Jounce; PhD Biosciences
Speaker or member of speakers bureau for: Regeneron; Sanofi
Stock options from: Lazarus
Owns stock (publicly traded) in: Science 37

Faculty

Douglas Grossman, MD, PhD

Professor of Dermatology
Co-Leader Melanoma Center
Huntsman Cancer Institute
University of Utah School of Medicine
Salt Lake City, Utah

Disclosures

Douglas Grossman, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Orlucent
Contracted researcher for: Dermtech; Orlucent; Skin Analytics

David M. Miller, MD, PhD, FAAD

Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multidisciplinary Clinic
Massachusetts General Cancer Center
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Boston, Massachusetts

Disclosures

David M. Miller, MD, PhD, FAAD, has the following relevant financial relationships:
Consultant or advisor for: Castle Biosciences; Checkpoint; EMD Serono; Merck KGaA; Merck Sharp & Dohme, Corp.; Pfizer; Regeneron; Sanofi Genzyme
Research funding from: Kartos; NeoImmune Tech; Regeneron
Stock options from: Checkpoint
Owns stock (publicly traded) in: Checkpoint

Steven Q. Wang, MD, FAAD

Chief of Dermatologic Oncology & Dermatologic Surgery
Director of Dermatologic Oncology
Hoag Family Cancer Institute
Hoag Memorial Hospital Presbyterian
Newport Beach, California

Disclosures

Steven Q. Wang, MD, FAAD, has no relevant financial relationships.

Editor

Laura M Biezup, MD, MSt.

Medical Education Director, Medscape, LLC

Disclosures

Laura M. Biezup, MD, MSt, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC / CE

Cutaneous Malignancies

Authors: Vishal A. Patel, MD; Douglas Grossman, MD, PhD; David M. Miller, MD, PhD, FAAD; Steven Q. Wang, MD, FAAD
CME / ABIM MOC / CE Released: 11/29/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/29/2023, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for dermatologists, oncologists, surgeons, primary care physicians (PCPs), nurses, nurse practitioners (NPs), and physician assistants (PAs) involved in the care of patients with cutaneous malignancies.

The goal of this activity is for the learner to be better able to diagnose cutaneous malignancies and develop treatment plans in a variety of patients.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Diagnostic methods used to identify patients with cutaneous malignancies
- Use of prognostic gene expression profiling
Have greater competence related to
- Creating customized care plans for patients with cutaneous malignancies

Disclosures

Disclosures for additional planners can be found here.

Session Chair

Vishal A. Patel, MD

Director of Cutaneous Oncology
GW Cancer Center
Associate Professor of Dermatology and Oncology
George Washington University
School of Medicine & Health Sciences
Washington, DC

Disclosures

Vishal A. Patel, MD, has the following relevant financial relationships:
Consultant or advisor for: Almirall; Jounce; PhD Biosciences
Speaker or member of speakers bureau for: Regeneron; Sanofi
Stock options from: Lazarus
Owns stock (publicly traded) in: Science 37

Faculty

Douglas Grossman, MD, PhD

Professor of Dermatology
Co-Leader Melanoma Center
Huntsman Cancer Institute
University of Utah School of Medicine
Salt Lake City, Utah

Disclosures

Douglas Grossman, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Orlucent
Contracted researcher for: Dermtech; Orlucent; Skin Analytics

David M. Miller, MD, PhD, FAAD

Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multidisciplinary Clinic
Massachusetts General Cancer Center
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Boston, Massachusetts

Disclosures

David M. Miller, MD, PhD, FAAD, has the following relevant financial relationships:
Consultant or advisor for: Castle Biosciences; Checkpoint; EMD Serono; Merck KGaA; Merck Sharp & Dohme, Corp.; Pfizer; Regeneron; Sanofi Genzyme
Research funding from: Kartos; NeoImmune Tech; Regeneron
Stock options from: Checkpoint
Owns stock (publicly traded) in: Checkpoint

Steven Q. Wang, MD, FAAD

Chief of Dermatologic Oncology & Dermatologic Surgery
Director of Dermatologic Oncology
Hoag Family Cancer Institute
Hoag Memorial Hospital Presbyterian
Newport Beach, California

Disclosures

Steven Q. Wang, MD, FAAD, has no relevant financial relationships.

Editor

Laura M Biezup, MD, MSt.

Medical Education Director, Medscape, LLC

Disclosures

Laura M. Biezup, MD, MSt, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Dermatology

CME / ABIM MOC / CE

Cutaneous Malignancies

Authors: Vishal A. Patel, MD; Douglas Grossman, MD, PhD; David M. Miller, MD, PhD, FAAD; Steven Q. Wang, MD, FAADFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 11/29/2022

Valid for credit through: 11/29/2023, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Photoprotection for Skin Cancer: Is it for Everyone?

Should you recommend sun protection for all your patients?
Steven Q. Wang, MD

Skin Cancer Screening: Utility of Lack Thereof?

Do all patients need an annual skin examination?
Vishal A. Patel, MD

Prognostic Gene Expression Profiling for Melanoma: Is it Ready for Routine Use?

Should all patients with melanoma undergo gene expression profiling?
Douglas Grossman, MD, PhD.

Prognostic Gene Expression Profiling for Squamous Cell Carcinoma: Does it Add to Staging?

Will gene expression profiling reveal relevant prognostic information for patient with squamous cell carcinoma?
David M. Miller, MD, PhD.

Cutaneous Malignancies Roundtable Discussion: How Would You Manage This Patient?

How would you help these patients?
Vishal A. Patel, MD; Steven Q. Wang, MD; Douglas Grossman, MD, PhD; David M. Miller, MD, PhD.

Page 1 of 6

Photoprotection for Skin Cancer: Is it for Everyone?

CME / ABIM MOC / CE Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Session Chair

Vishal A. Patel, MD

Faculty

Douglas Grossman, MD, PhD

David M. Miller, MD, PhD, FAAD

Steven Q. Wang, MD, FAAD

Editor

Laura M Biezup, MD, MSt.

Compliance Reviewer

Yaisanet Oyola, MD

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Cutaneous Malignancies

Target Audience and Goal Statement

Disclosures

Session Chair

Vishal A. Patel, MD

Faculty

Douglas Grossman, MD, PhD

David M. Miller, MD, PhD, FAAD

Steven Q. Wang, MD, FAAD

Editor

Laura M Biezup, MD, MSt.

Compliance Reviewer

Yaisanet Oyola, MD

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Cutaneous Malignancies

Contents of This CME Activity

Photoprotection for Skin Cancer: Is it for Everyone?

Skin Cancer Screening: Utility of Lack Thereof?

Prognostic Gene Expression Profiling for Melanoma: Is it Ready for Routine Use?

Prognostic Gene Expression Profiling for Squamous Cell Carcinoma: Does it Add to Staging?

Cutaneous Malignancies Roundtable Discussion: How Would You Manage This Patient?